EU antitrust regulators have resumed their scrutiny of US life sciences company Illumina’s bid for Grail after a two-month temporary halt and will decide by February 4 whether to clear the deal, a European Commission filing showed on Tuesday, October 12.
The EU competition enforcer paused its investigation on August 11 while waiting for Illumina to provide requested data.
It restarted the clock on October 7. Last month, it sent a statement of objections to Illumina for closing the deal before securing regulatory clearance, warning of interim measures.
Illumina finalized the deal in August and stated it would hold Grail as a separate company while waiting for the EU green light. Even though Illumina and Grail have pledged to keep their business operations separate pending final reviews, being officially found in breach of the EU’s “standstill obligation” or other merger regulations could lead to fines of up to 10% of each party’s annual worldwide turnover—which for Illumina alone topped US$3.2 billion in 2020—and the Commission stated that, in its preliminary view, the companies had already done so.
European antitrust watchdogs and the US Federal Trade Commission (FTC) have stated the deal could give Illumina an opportunity to throttle the R&D progress of potential cancer diagnostic competitors due to its weighty global market share in the necessary DNA analysis hardware.
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
DOJ and FTC Introduce Website for Reporting Anti-Competitive Healthcare Practices
Apr 18, 2024 by
CPI
US Congress Advances Legislation to Compel TikTok Sale
Apr 18, 2024 by
CPI
UK Financial Sector Advocates Enhanced Regulatory Accountability
Apr 18, 2024 by
CPI
Google and All 50 States Defend $700 Million Consumer Settlement
Apr 18, 2024 by
CPI
Colorado Enacts First Law to Protect Consumer Brainwave Data
Apr 18, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI